Biopharmaceutical company focused on identifying, developing and commercializing therapies for rare diseases, with an emphasis on rare kidney and metabolic conditions; markets FILSPARI (sparsentan) for IgA nephropathy.
Bradley Campbell succeeds Eric Dube as CEO
Eric Dube's executive advisor term ends
Travere Therapeutics CEO Eric Dube is stepping down after overseeing the launch of rare kidney disease drug Filspari, with a former Amicus Therapeutics chief executive taking over, according to Fierce Biotech's Chutes & Ladders leadership roundup.
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will step down.
Chief Executive Officer (stepping down; remains executive advisor through February 2027)
Chief Executive Officer, effective December 1, 2026